Haemacure announces webcast of presentation at EQUITIES magazine 56th Anniversary Spring Conference 2007 investor meeting


    MONTREAL, April 18 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a
specialty biotherapeutics company developing high-value human proteins, today
announced the webcast of its presentation at EQUITIES Magazine's 56th
Anniversary Spring Conference 2007 on Friday, April 20, 2007 at The Yale Club
in New York, New York, live from 9:30 to 10:00 am, EST.
    EQUITIES will webcast the audio portion of the presentation and post the
associated slides via its website at www.equitiesmagazine.com. To access the
live broadcast via internet in listen-only mode, or the subsequently archived
recording, please cut and paste the following link directly into your web


    Please visit the site at least five minutes prior to start time for

    About EQUITIES

    EQUITIES Magazine ("EQUITIES"), based in Santa Monica, California, is a
division of Equities Global Communications, Inc. For 27 years EQUITIES has
held investor awareness conferences, bringing together the most active and
respected small and mid-cap buy-side investment professionals with small and
mid-cap companies. EQUITIES publications have a U.S. readership of
approximately 175,000 brokers, hedge funds, chief executive officers, chief
financial officers, portfolio managers and retail investors, and more than
37,000 readers of its European version. For further information, visit

    About Haemacure

    Haemacure Corporation is a specialty biotherapeutics company developing
high-value human therapeutic proteins for commercialization. Haemacure's
research and development effort is driven by its proprietary plasma protein
extraction technology to develop next-generation products, including surgical
    Hemaseel(TM)HMN, Haemacure's lead product candidate, is a human-derived
fibrin sealant in late-stage clinical development. Haemacure's second product
candidate is human thrombin, a component of its fibrin sealant. Both
candidates have applications in the expanding biosurgical market. Follow-on
development will focus on surgical hemostats, biomaterial combinations and
drug delivery in select therapeutic areas. Haemacure has recently discovered
additional specialty proteins in its plasma-derived intermediates and will
advance these specialty proteins through partnerships with other
pharmaceutical and biotechnology companies.

    Forward-looking Statements

    Certain statements contained in this news release and oral statements
made by representatives of Haemacure that are not historical facts may be
considered forward-looking statements. Such statements, based as they are on
the current expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
Corporation does business, stock market volatility, fluctuations in costs, the
ability of Haemacure to set up its planned manufacturing facility, the
completion and outcome of clinical studies as well as the development of new
products, and changes to the competitive environment due to consolidation or
otherwise. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. Haemacure
Corporation disclaims any intention or obligation to update these statements.

For further information:

For further information: Gilles Lemieux, Secretary, Haemacure
Corporation, (514) 282-3350 ext. 22, glemieux@haemacure.com; IR Contact: Dory
Valiquette, LaVoie Group, (978) 745-4200 ext. 106,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890